Solstice Neurosciences Inc.
Sorry, there's no topic page that matches your search.
Want us to make one for it?
To help you find out more, we've searched for your term on Google
|
Web
(8)
|
Solstice Neurosciences, Inc. is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty ...
www.solsticeneuro.com
www.solsticeneuro.com
Solstice Neurosciences, Inc. (Solstice) is a privately-held specialty biopharmaceutical company originally formed by four investor groups. ...
www.biospace.com
www.biospace.com
Solstice Neurosciences, Inc., a biopharmaceutical company, engages in the development, manufacture, marketing, and sale of biopharmaceutical products. ...
www.linkedin.com
www.linkedin.com
Solstice Neurosciences Inc. www.solsticeneuro.com ... Series B round of $85mm is raised for Solstice Neurosciences, 11/2006 ...
companies.windhover.com
companies.windhover.com
Elan Sells Its Myobloc Rights to Solstice Neurosciences Inc. - DUBLIN, Ireland - - Elan Corporation, plc today announced that it has : Encyclopedia.com.
www.encyclopedia.com
www.encyclopedia.com
Solstice Neurosciences, Inc. Announces Commercialization Agreement. from PR Newswire. Highbeam Research – FREE Trial.
www.highbeam.com
www.highbeam.com
Research and review Solstice Neurosciences, Inc. jobs. Learn more about a career with Solstice Neurosciences, Inc. including all recent jobs, hiring trends, ...
www.indeed.com
www.indeed.com
Demandbase - Solstice Neurosciences Inc Business Directory and business contact information for lead generation, b2b marketing and sales prospecting.
www.demandbase.com
www.demandbase.com
Get Solstice Neurosciences, Inc. company research & investing information. Find executive management and the latest company developments.
investing.businessweek.com
investing.businessweek.com
Solstice Neurosciences, Inc. and Eisai Co, Ltd., Tokyo, Japan have entered into a commercialization agreement for NeuroBloc(R) (Botulinum Toxin Type B) ...
www.prnewswire.co.uk
www.prnewswire.co.uk
1
2
3
4
5
6
7
8
